Reanalysis of Acute Myeloid Leukemia 4- or 11- Gene Panels, Additional Genes
Use
Comprehensive reanalysis of a larger set of genes/gene regions when a more targeted gene panel was previously performed in this laboratory. Evaluation of known or suspected hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm, unexplained cytopenias) at the time of diagnosis or possibly disease relapse, to help determine diagnostic classification and provide prognostic or therapeutic information for helping guide clinical management. Determine the presence of new clinically important gene mutation changes at relapse.
Special Instructions
Only orderable as a reflex. Reflex testing is available upon request within 6 months of original NGAMT / MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next Generation Sequencing, Varies or NGAML / MayoComplete Acute Myeloid Leukemia, 11-Gene Panel, Varies sample submission. This is a bioinformatics review of additional gene regions not analyzed in the previously ordered tests.
Limitations
This test will not detect genetic abnormalities in genes or regions outside the specified target areas. The test detects single base substitutions (ie, point mutations) as well as small insertion or deletion type events, but does not detect gene rearrangements (ie, translocations), gene fusions, copy number alterations, or large scale (segmental chromosome region) deletions and complex changes. This assay does not distinguish between somatic and germline alterations, particularly with variant allele frequencies near 50% or 100%. A low incidence of gene mutations associated with myeloid neoplasms can be detected in nonmalignant hematopoietic cells in individuals with advancing age (clonal hematopoiesis of indeterminate potential), and these may not be clearly distinguishable from tumor-associated mutations. Prior treatment for hematologic malignancy could affect results obtained in this assay, especially following an allogeneic hematopoietic stem cell transplant.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 99961-5
- 31208-2
- 29308-4
- 82939-0
- 69047-9
- 82786-5
- 93367-1
- 48767-8
- 85069-3
- 36908-2
- 18771-6
- 62364-5
Result Turnaround Time
16-21 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Not provided
Minimum Volume
Not provided
Storage Instructions
Varies